The Greater Cannabis Company, Inc. (GCAN)
OTCMKTS: GCAN · Delayed Price · USD
0.0006
0.00 (0.00%)
Mar 28, 2024, 1:44 PM EDT - Market closed
Company Description
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics.
It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body.
The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders.
The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.
The Greater Cannabis Company, Inc.
Country | MD |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 1 |
CEO | Aitan Zacharin |
Contact Details
Address: 15 Walker Ave, Suite 101 Baltimore, Maryland 21208 United States | |
Phone | (443) 738-4051 |
Website | gcanrx.com |
Stock Details
Ticker Symbol | GCAN |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001695473 |
CUSIP Number | 391657103 |
ISIN Number | US3916571033 |
Employer ID | 30-0842570 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Aitan Zacharin | Chairman, President, Chief Executive Officer, Acting Chief Financial Officer and Treasurer |
Motti Stenge | Chief Operating Officer |
Dr. Adi Aran M.D. | Chief Scientific Advisor |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 26, 2024 | PRER14C | Filing |
Nov 13, 2023 | 10-Q | Quarterly Report |
Aug 16, 2023 | 8-K | Current Report |
Aug 14, 2023 | 10-Q | Quarterly Report |
May 12, 2023 | 10-Q | Quarterly Report |
Apr 13, 2023 | 10-K | Annual Report |
Apr 3, 2023 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
Jan 26, 2023 | 8-K | Current Report |
Nov 21, 2022 | PRE 14A | Other preliminary proxy statements |
Nov 14, 2022 | 10-Q | Quarterly Report |